Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Carisma Therapeutics (CARM) announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapy for hepatocellular carcinoma, or HCC, ...

Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...

MB-109 is Mustang's regimen that combines MB-101, a chimeric antigen receptor (CAR)-T-cell therapy targeting interleukin 13 ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for hepatocellular carcinoma ("HCC"), developed in ...

To date, the Food and Drug Administration (FDA) has approved six chimeric antigen receptor (CAR) T cell therapy products targeting CD19 and BCMA for B-cell lymphomas, leukemias and multiple myeloma, ...

The international Phase 1 study, called CARLYSE, is the first in the UK to assess the potential of CAR-T (Chimeric Antigen ...

ALLO-316, a CD70-targeting CAR T-cell therapy, has demonstrated activity in patients with previously treated, advanced ccRCC.

MB-108 shows activity and is well tolerated in recurrent glioblastoma, with preclinical data supporting its combination with ...

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET) ...